Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How Is Colorectal Cancer Care Impacted by Global Crisis in Contrasting Healthcare Systems?-A Descriptive Study From Scotland and Switzerland During the COVID-19 Pandemic.

World journal of surgery·2026
Same author

Quantifying physician's bias to terminate resuscitation. The TERMINATOR study.

Resuscitation·2023
Same author

Simple Wound Irrigation in the Postoperative Treatment for Surgically Drained Spontaneous Soft Tissue Abscesses: A Prospective, Randomized Controlled Trial.

World journal of surgery·2020
Same author

Genome-wide association analysis for lethal brachycephalic-like facial dysmorphia in Labrador Retrievers.

Animal genetics·2019
Same author

Genetic risk factors for osteochondrosis in various horse breeds.

Equine veterinary journal·2018
Same author

The proteome pattern cGvHD_MS14 allows early and accurate prediction of chronic GvHD after allogeneic stem cell transplantation.

Leukemia·2016
Same journal

A Kidney Transplant Recipient with Severe Chronic Diarrhea and Villous Atrophy.

Gastroenterology·2026
Same journal

A Clinical Perspective on Comparative Models of Pancreatic Cyst Surveillance.

Gastroenterology·2026
Same journal

Reply to Jiang et al.

Gastroenterology·2026
Same journal

An Unusual Cause of Chronic Hematochezia.

Gastroenterology·2026
Same journal

How important is fiber in the Crohn's disease story?

Gastroenterology·2026
Same journal

Reply to "Critical Appraisal of the Integrin αV-YAP-CTGF Axis in Congestive Hepatopathy".

Gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Jul 6, 2026

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

Sulindac (Clinoril) hepatitis

A K Dhand, D R LaBrecque, J Metzger

    Gastroenterology
    |March 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Sulindac can cause liver injury, confirmed by recurring symptoms upon re-exposure. This suggests a hypersensitivity reaction to the nonsteroidal anti-inflammatory drug.

    More Related Videos

    Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube
    06:12

    Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube

    Published on: April 28, 2020

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
    11:06

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

    Published on: January 31, 2022

    Related Experiment Videos

    Last Updated: Jul 6, 2026

    Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
    11:36

    Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

    Published on: May 29, 2020

    Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube
    06:12

    Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube

    Published on: April 28, 2020

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
    11:06

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

    Published on: January 31, 2022

    Area of Science:

    • Hepatology
    • Clinical Pharmacology
    • Immunology

    Background:

    • Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
    • Drug-induced liver injury (DILI) is a significant concern in clinical practice.
    • Sulindac is an NSAID with a known, albeit rare, potential for adverse hepatic effects.

    Observation:

    • A patient presented with symptoms suggestive of liver disease after Sulindac administration.
    • The patient experienced a recurrence of hepatic dysfunction upon inadvertent re-exposure to Sulindac.
    • Symptoms including fever, rash, and abnormal liver tests resolved upon drug withdrawal.

    Findings:

    • Sulindac was identified as the causative agent for the patient's hepatitis.
    • The rapid recurrence and resolution pattern strongly indicated a hypersensitivity reaction.
    • The clinical presentation pointed towards an immune-mediated mechanism rather than direct toxicity.

    Implications:

    • This case highlights the importance of considering hypersensitivity reactions in NSAID-induced liver injury.
    • Clinicians should maintain a high index of suspicion for Sulindac-induced hepatitis, especially with recurrent exposure.
    • Awareness of this adverse effect can guide prompt diagnosis and management, preventing further liver damage.